The new diabetes inhalers: New tools for the clinician William T. Cefalu Invited Commentary 05 July 2007 Pages: 165 - 167
ADOPT: Lessons from Comparison of Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Hannele Yki-Jarvinen Clinical trials report 05 July 2007 Pages: 173 - 174
NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes Elisabetta BugianesiEster VanniGiulio Marchesini OriginalPaper 05 July 2007 Pages: 175 - 180
Nonalcoholic fatty liver disease and cardiovascular disease risk Roger K. SchindhelmMichaela DiamantRobert J. Heine OriginalPaper Open access 05 July 2007 Pages: 181 - 187
Antihypertensive agents, insulin sensitivity, and new-onset diabetes Pantelis A. SarafidisSamy I. McFarlaneGeorge L. Bakris OriginalPaper 05 July 2007 Pages: 191 - 199
Prevention of type 2 diabetes: An update Amal FaragJocelyne KaramSamy I. McFarlane OriginalPaper 05 July 2007 Pages: 200 - 207
Hypertension in people with diabetes and the metabolic syndrome: Pathophysiologic insights and therapeutic update Sudha GanneSurender K. AroraAdam Whaley-Connell OriginalPaper 05 July 2007 Pages: 208 - 217
Pioglitazone and Nonalcoholic Steatohepatitis Guenther Boden Clinical trials report 05 July 2007 Pages: 221 - 222
Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation Guenther BodenA. Koneti Rao OriginalPaper 05 July 2007 Pages: 223 - 227
Dyslipidemia in type 2 diabetes mellitus Ramprasad GadiFrederick F. Samaha OriginalPaper 05 July 2007 Pages: 228 - 234
Glycotoxins in the diet promote diabetes and diabetic complications Helen VlassaraGary Striker OriginalPaper 05 July 2007 Pages: 235 - 241
Inflammatory mechanisms of diabetic complications Michael D. WilliamsJerry L. Nadler OriginalPaper 05 July 2007 Pages: 242 - 248